Titre

Long-term efficacy of ciliary muscle gene transfer of three sFlt-1 variants in a rat model of laser-induced choroidal neovascularization.

Type
article
Institution
UNIL/CHUV/Unisanté + institutions partenaires
Périodique
Auteur(s)
El Sanharawi, M.
Auteure/Auteur
Touchard, E.
Auteure/Auteur
Benard, R.
Auteure/Auteur
Bigey, P.
Auteure/Auteur
Escriou, V.
Auteure/Auteur
Mehanna, C.
Auteure/Auteur
Naud, M.C.
Auteure/Auteur
Berdugo, M.
Auteure/Auteur
Jeanny, J.C.
Auteure/Auteur
Behar-Cohen, F.
Auteure/Auteur
Liens vers les personnes
Liens vers les unités
ISSN
1476-5462
Statut éditorial
Publié
Date de publication
2013
Volume
20
Première page
1093
Dernière page/numéro d’article
1103
Peer-reviewed
Oui
Langue
anglais
Notes
Publication types: JOURNAL ARTICLE
Résumé
Inhibition of vascular endothelial growth factor (VEGF) has become the standard of care for patients presenting with wet age-related macular degeneration. However, monthly intravitreal injections are required for optimal efficacy. We have previously shown that electroporation enabled ciliary muscle gene transfer results in sustained protein secretion into the vitreous for up to 9 months. Here, we evaluated the long-term efficacy of ciliary muscle gene transfer of three soluble VEGF receptor-1 (sFlt-1) variants in a rat model of laser-induced choroidal neovascularization (CNV). All three sFlt-1 variants significantly diminished vascular leakage and neovascularization as measured by fluorescein angiography (FA) and flatmount choroid at 3 weeks. FA and infracyanine angiography demonstrated that inhibition of CNV was maintained for up to 6 months after gene transfer of the two shortest sFlt-1 variants. Throughout, clinical efficacy was correlated with sustained VEGF neutralization in the ocular media. Interestingly, treatment with sFlt-1 induced a 50% downregulation of VEGF messenger RNA levels in the retinal pigment epithelium and the choroid. We demonstrate for the first time that non-viral gene transfer can achieve a long-term reduction of VEGF levels and efficacy in the treatment of CNV.Gene Therapy advance online publication, 27 June 2013; doi:10.1038/gt.2013.36.
PID Serval
serval:BIB_21D5F99F2B7F
DOI
PMID
WOS
Permalien
Date de création
2013-08-19T13:55:36.271Z
Date de création dans IRIS
2025-05-20T20:08:12Z